Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Seer, Inc.NASDAQ: SEER

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $18.24M fell 20.0% year over year, behind the -18.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.

Context

  • Operating expenses amounted to 498.5% of revenue in FY2025, down 268.2 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.0% toward the trailing-twelve-month pace of -18.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.24M-6.8% QoQ
Last fiscal yearDec 2025
$80.35M-24.9% YoY
LTMMar 2026
$81.9M-18.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.0%——
1 year-24.9%——
3-year CAGR-6.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
80.35M USD
Year-over-year change
-24.9%
4-year CAGR
+3.0%

Operating Expenses vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.3% is the 14th highest of 19, against a peer median of +2.2%.
  • Operating expenses amounts to 544.6% of revenue for SEER, versus a peer median of 440.5%.
SEER Competitors
Operating Expenses for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$457.25M USD+29.0%+23.1%435.5%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$370.78M USD+82.6%+75.7%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$317.52M USD+142.5%+109.8%45.2%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$240.35M USD+15.1%——
SANASana Biotechnology, Inc.LTM Mar 2026$235.17M USD+10.6%-13.2%—
PHVSPharvaris N.V.LTM Sep 2026€193.36M EUR+125.2%+25.1%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$189.56M USD-47.4%-10.9%611487.1%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$189.2M USD+18.6%+14.7%440.5%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$149.59M USD+2.2%+15.6%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$146.9M USD-2.4%-6.2%421.4%
NKTXNkarta, Inc.LTM Mar 2026$113.97M USD-13.7%-2.0%—
QSIQuantum-Si incorporatedLTM Mar 2026$97.04M USD-13.5%-7.3%5239.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$87.05M USD-28.0%-7.0%308.4%
SEERSeer, Inc.LTM Mar 2026$81.9M USD-18.3%-6.5%544.6%
PEPGPepGen Inc.LTM Mar 2026$79.52M USD-27.0%+10.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
STTKShattuck Labs, Inc.LTM Mar 2026$51.84M USD-32.4%+34.1%5184.4%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.12M USD-25.8%-3.3%—
MNOVMediciNova, Inc.LTM Mar 2026$13.01M USD+2.1%-3.1%2180.0%
Peer median (excluding SEER) —+2.2%-2.0%440.5%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.